Format

Send to

Choose Destination
Drug Discov Today. 2015 Feb;20(2):255-61. doi: 10.1016/j.drudis.2014.09.025. Epub 2014 Oct 7.

Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery.

Author information

1
Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA.
2
Department of Medicine, Division of Nephrology, Vanderbilt University, Nashville, TN 37232, USA.
3
Department of Medicine, Division of Nephrology, Vanderbilt University, Nashville, TN 37232, USA; Department of Medicine, Veterans Affairs Hospital, Nashville, TN 37232, USA.
4
Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: jens.meiler@vanderbilt.edu.

Abstract

Discoidin domain receptor (DDR) 1 and 2 are transmembrane receptors that belong to the family of receptor tyrosine kinases (RTK). Upon collagen binding, DDRs transduce cellular signaling involved in various cell functions, including cell adhesion, proliferation, differentiation, migration, and matrix homeostasis. Altered DDR function resulting from either mutations or overexpression has been implicated in several types of disease, including atherosclerosis, inflammation, cancer, and tissue fibrosis. Several established inhibitors, such as imatinib, dasatinib, and nilotinib, originally developed as Abelson murine leukemia (Abl) kinase inhibitors, have been found to inhibit DDR kinase activity. As we review here, recent discoveries of novel inhibitors and their co-crystal structure with the DDR1 kinase domain have made structure-based drug discovery for DDR1 amenable.

PMID:
25284748
PMCID:
PMC4336622
DOI:
10.1016/j.drudis.2014.09.025
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center